Insulet (PODD) Expected to Announce Quarterly Earnings on Wednesday

Insulet (NASDAQ:PODD) is projected to issue its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect Insulet to post earnings of $1.48 per share and revenue of $768.3080 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 18, 2026 at 8:00 AM ET.

Insulet Trading Up 2.8%

Shares of NASDAQ:PODD opened at $252.41 on Wednesday. The firm has a market capitalization of $17.76 billion, a price-to-earnings ratio of 73.16, a price-to-earnings-growth ratio of 1.39 and a beta of 1.41. The business’s 50 day moving average price is $281.06 and its 200-day moving average price is $307.47. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18. Insulet has a 1 year low of $230.05 and a 1 year high of $354.88.

Hedge Funds Weigh In On Insulet

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Measured Wealth Private Client Group LLC purchased a new stake in shares of Insulet in the 3rd quarter valued at approximately $49,000. Osterweis Capital Management Inc. purchased a new position in Insulet in the 2nd quarter valued at $51,000. NewEdge Advisors LLC raised its holdings in Insulet by 44.8% during the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 64 shares in the last quarter. MUFG Securities EMEA plc purchased a new stake in shares of Insulet in the second quarter valued at approximately $65,000. Finally, Brown Brothers Harriman & Co. increased its holdings in shares of Insulet by 44.6% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 227 shares of the medical instruments supplier’s stock valued at $70,000 after purchasing an additional 70 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PODD. Wolfe Research lifted their target price on shares of Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of Insulet in a report on Thursday, January 22nd. Leerink Partners raised their target price on Insulet from $385.00 to $386.00 and gave the company an “outperform” rating in a research report on Friday, November 21st. Evercore initiated coverage on Insulet in a research note on Tuesday, December 16th. They issued an “outperform” rating and a $370.00 price target on the stock. Finally, UBS Group reissued a “buy” rating on shares of Insulet in a research note on Thursday, December 18th. Twenty analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $374.10.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.